Andy Hahn
@OncHahn
Followers
2K
Following
7K
Media
198
Statuses
1K
Genitourinary Medical Oncologist @MDAndersonNews. Opinions are my own.
Houston, TX
Joined December 2016
An IM residency will be lucky to have @MourattJulia join their team! We’ve been lucky to have her here @MDAndersonNews.
Hi #MedTwitter!!. I’m Julia, a first-gen MD from Brazil and a research fellow at @MDAndersonNews, excited to apply to Internal Medicine in the #Match2026!. Outside of work I enjoy walks with my dog, exploring stoicism, baking desserts, and discovering new coffee shops. I’d love
1
2
6
RT @APCCC_Lugano: Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer:….
0
28
0
RT @AttardLab: Excited to share our study Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostat….
0
27
0
Here a recap of a talk on "Future Directions in mCRPC" highlighting some of the near and mid-term studies that we're excited about for men with metastatic CRPC, Thanks to @urotoday and @zklaassen_md!.
urotoday.com
Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through...
0
5
12
RT @neerajaiims: Just in @JAMANetworkOpen 👉 In pt level data from two ph3 trials (n=2187) 👉statin use associated with ⬆️ OS in advanced #pr….
0
40
0
RT @NickSalgia: Excited to share the bulk of my thesis work available online today @CancerCell. We sought to dive into the tumor microenvir….
0
24
0
RT @nsayeghmd: 👉🏻Just in @JCO_ASCO: We explore how biomarker-driven, rational combos may unlock ICI potential in mCRPC #prostatecancer 👇🏻 P….
0
22
0
RT @ChadTangMD: Amazing work led by Alex Sherry! @piet_ost @ebludmir @OncHahn @MDAndersonNews @VedangMurthy @drdavidpalma @d_shapiro1 @_Sha….
0
13
0
RT @brian_rini: Final KN426 clinical and translational data published @NatureMedicine. The balance of inflammation / angiogenesis impacts….
nature.com
Nature Medicine - Five-year follow-up and prespecified exploratory biomarker analysis from the phase 3 KEYNOTE-426 trial show that pembrolizumab plus axitinib compared to sunitinib as first-line...
0
40
0
RT @PavlosMsaouel: 1/5 Should we always combine bevacizumab (anti‑VEGF)& erlotinib (anti-EGFR) in rare #kidneycancer? We dissected @MCT_AAC….
0
13
0
RT @ED_PhD_: 🔥HOT OFF THE PRESS🔥.Our latest paper by @sergio_42 on the effects of #Radium223 on the #BoneMicroenvironment is out in @ActaPh….
0
5
0
RT @neerajaiims: Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in….
0
61
0
RT @crisbergerot: Huge congrats to @JasnoorMalhotra and #ASchlager on this important paper @EurUrolFocus reviewing HRQOL assessments in mRC….
0
16
0
RT @neerajaiims: Breaking News from ph3 Embark trial👉Enzalutamide+ADT improve overall survival (OS) vs. ADT alone in Non-Metastatic HSPC #P….
0
64
0
RT @PavlosMsaouel: 1/5 How reproducible are phase III oncology trials?.📊 With @AlexSherryMD @ErikVanZwet @ebludmir et al. We analyzed 632 R….
0
36
0
RT @APCCC_Lugano: Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial….
0
32
0
RT @PavlosMsaouel: 1/5 #RenalMedullaryCarcinoma (RMC) is a lethal #KidneyCancer in young people with #SickleCellTrait (SCT). Our new prospe….
0
22
0
RT @PavlosMsaouel: 🚀 Now enrolling @MDAndersonNews: IVORY trial of #ivonescimab (first-in-class PD1×VEGF bispecific) in metastatic clear ce….
0
29
0
RT @PavlosMsaouel: Tremendously enjoyed working with @Shounak_Gupta et al on this contemporary update of #RenalMedullaryCarcinoma pathology….
0
9
0